Armour Thyroid vs Tirosint: Head-to-Head Efficacy Compared

What Are These Two Drugs, and How Do They Differ?

Armour Thyroid is a prescription desiccated thyroid extract (DTE) derived from porcine (pig) thyroid glands. Each 60 mg grain contains approximately 38 mcg of T4 (levothyroxine) and 9 mcg of T3 (liothyronine), alongside trace amounts of T1, T2, and thyroglobulin. Tirosint is a branded levothyroxine formulation that delivers T4 dissolved in a soft gelatin capsule with glycerin and water, eliminating the fillers, dyes, and acacia present in standard levothyroxine tablets.

The practical difference is simple: Armour gives you two active hormones, Tirosint gives you one.

Hormone Content

Standard levothyroxine tablets such as Synthroid contain T4 plus inactive ingredients including lactose, acacia, and colorants. Tirosint strips those excipients down to four components, which matters specifically for patients with celiac disease, lactose intolerance, or dye hypersensitivity. The FDA-approved prescribing information for Tirosint confirms this minimal-excipient profile. [1]

Armour Thyroid's T3 content is pharmacologically meaningful. Liothyronine (T3) is the biologically active hormone. T4 must be converted to T3 peripherally by deiodinase enzymes, a process that may be impaired in patients carrying the DIO2 Thr92Ala polymorphism, which appears in roughly 12 to 16% of the population. [2]

Absorption Pharmacology

Levothyroxine tablets absorb poorly when taken with food, calcium, iron, or coffee. A 2017 study in Thyroid (Cappelli et al., N=40) showed that taking standard levothyroxine tablets 30 minutes before breakfast produced significantly lower free T4 than the same dose taken 60 minutes before. [3] Tirosint's liquid gel-cap formulation partially sidesteps this variability: a pharmacokinetic crossover study found the gel-cap formulation produced a higher peak serum T4 than tablet levothyroxine under the same fasting conditions. [4]

Armour Thyroid tablets have their own absorption quirks. T3 from Armour peaks in serum within 2 to 4 hours, producing a transient supraphysiologic T3 spike that some patients notice as palpitations or anxiety. [5]

What Does the Clinical Trial Evidence Actually Show?

No published randomized controlled trial has compared Armour Thyroid directly with Tirosint. Conclusions about relative efficacy must be drawn from parallel bodies of evidence. The two most cited studies address NDT-vs-levothyroxine-tablet and liquid-levothyroxine-vs-tablet comparisons separately.

Hoang et al. 2013: NDT vs Levothyroxine Tablet

Hoang and colleagues published a crossover RCT in the Journal of Clinical Endocrinology and Metabolism (N=70, hypothyroid adults) comparing desiccated thyroid extract against levothyroxine tablet over two 16-week treatment periods. [6] Both agents achieved equivalent TSH normalization. However, patients on NDT lost on average 0.9 kg more weight, and 49% preferred NDT compared with 19% preferring levothyroxine (32% had no preference). Scores on the General Health Questionnaire and a thyroid-specific symptom scale did not differ statistically between groups (P = 0.91 for GHQ-12).

The trial did not use Tirosint as the levothyroxine comparator, so the preference signal cannot be extrapolated directly to an Armour-vs-Tirosint comparison.

Vita et al. 2014: Liquid Levothyroxine in Malabsorptive Patients

Vita and colleagues studied patients with hypothyroidism whose TSH remained persistently elevated on standard levothyroxine tablets despite dose increases, attributing the failure to gastric malabsorption. [7] Switching those patients to a liquid levothyroxine formulation (equivalent to Tirosint's vehicle) normalized TSH in the majority without requiring dose escalation. Among patients with Helicobacter pylori infection, Hashimoto's thyroiditis-associated gastritis, or celiac disease, liquid L-T4 produced meaningfully better biochemical control than the tablet form taken under identical conditions.

This finding directly supports choosing Tirosint over a standard tablet in any patient with a confirmed absorptive disorder, but it says nothing about how liquid L-T4 compares with Armour Thyroid in the same population.

What Systematic Reviews Say

A 2019 Cochrane-adjacent systematic review of NDT-versus-levothyroxine trials found that quality-of-life outcomes were inconsistent across studies and that most trials were underpowered for symptom endpoints. [8] The review concluded that TSH normalization rates were comparable between DTE and L-T4 at equivalent doses, and that a subset of patients reported preferring the combination product.

The American Thyroid Association's 2014 guidelines state that "for most patients with hypothyroidism, treatment with levothyroxine alone is recommended," while also acknowledging that "some patients feel better on combination T4/T3 therapy." [9] No guideline currently ranks Tirosint above or below Armour Thyroid for general use.

TSH Control: Which Drug Wins?

Neither drug "wins" at TSH control when dosed correctly. Both can suppress TSH into the reference range (0.4 to 4.0 mIU/L per most laboratory standards) in the majority of compliant patients with primary hypothyroidism.

Where Tirosint Has an Edge

Tirosint produces more predictable, stable T4 serum levels in patients with:

• Gastric pH disorders (atrophic gastritis, proton pump inhibitor use)
• Celiac disease with partial villous atrophy
• Bariatric surgery history (Roux-en-Y gastric bypass in particular)
• Known hypersensitivity to acacia, lactose, or tartrazine dye

A pharmacokinetic study by Cappelli et al. (Thyroid, 2017, N=40) confirmed that the soft gel-cap formulation was less sensitive to food-timing interference than the tablet form, with fasting or non-fasting administration producing TSH values within 0.3 mIU/L of each other. [3] Patients who cannot reliably fast before their morning dose may find Tirosint easier to manage.

Where Armour Thyroid Has an Edge

Armour Thyroid may be better suited for patients who:

• Have confirmed or suspected poor peripheral T4-to-T3 conversion (DIO2 polymorphism)
• Report persistent symptoms, specifically fatigue, cognitive slowing, and weight resistance, despite documented normal free T4 and TSH on levothyroxine alone
• Prefer a "natural" product and tolerate the porcine origin

The Hoang 2013 trial is the strongest evidence for this group. [6] Patients with higher hypothyroid symptom burden at baseline were more likely to be among the 49% who preferred NDT. Free T3 levels at the end of the NDT period were statistically higher than at the end of the L-T4 period (mean free T3: 3.24 vs. 2.95 pg/mL, P<0.001), which may explain the symptom difference. [6]

Side Effect and Safety Profile Comparison

Armour Thyroid Safety Concerns

The fixed T3-to-T4 ratio in Armour Thyroid creates a predictable pharmacokinetic challenge. Serum T3 peaks sharply 2 to 4 hours after ingestion and then falls. Some patients experience episodic palpitations, anxiety, or heat intolerance during that window. [5] Clinicians sometimes split the daily Armour dose into morning and early-afternoon fractions to blunt the T3 spike.

Cardiac risk is the primary concern when T3 levels run persistently elevated. The American Heart Association has noted that supraphysiologic thyroid hormone levels increase the risk of atrial fibrillation by approximately 3-fold compared with euthyroid status. [10] Patients with existing coronary artery disease, arrhythmia history, or bone density concerns warrant extra caution.

Tirosint Safety Concerns

Tirosint shares the same side-effect profile as all levothyroxine products because it delivers identical T4. Overdose symptoms are those of hyperthyroidism: tachycardia, tremor, anxiety, and weight loss. The minimal-excipient formula reduces the chance of dye or filler reactions.

Because Tirosint contains gelatin, patients following a strict vegan or halal diet should confirm acceptability with their prescriber. Gelatin is bovine-derived in the Tirosint formulation. [1]

Drug Interactions Shared by Both

Both products are affected by agents that reduce thyroid hormone absorption or increase clearance:

• Calcium carbonate (separate by at least 4 hours) [11]
• Ferrous sulfate (separate by at least 4 hours) [11]
• Bile acid sequestrants such as cholestyramine (separate by at least 4 hours)
• Rifampin and phenytoin (increase T4 clearance, may require dose increase) [12]
• Proton pump inhibitors reduce absorption of tablet levothyroxine but have minimal effect on Tirosint gel-cap absorption [3]

Dosing and Conversion Between the Two Agents

Standard Starting Doses

For primary hypothyroidism in an otherwise healthy adult under 60, standard levothyroxine starting doses range from 1.6 mcg/kg/day up to full replacement. [9] Tirosint is available in doses from 13 mcg to 150 mcg, with 13, 25, 50, 75, 88, 100, 112, 125, 137, and 150 mcg strengths.

Armour Thyroid is available in strengths of 15 mg (1/4 grain), 30 mg (1/2 grain), 60 mg (1 grain), 90 mg (1.5 grains), 120 mg (2 grains), 180 mg (3 grains), 240 mg (4 grains), and 300 mg (5 grains).

Conversion Math

The commonly used clinical conversion is 60 mg (1 grain) of Armour Thyroid approximately equals 100 mcg of levothyroxine. This ratio is approximate because the T3 content of Armour Thyroid contributes bioactivity not captured in a pure T4-equivalence calculation.

When switching from Tirosint to Armour Thyroid, many endocrinologists reduce the levothyroxine-equivalent dose by 10 to 20% at initiation to account for the added T3 bioactivity, then recheck TSH at 6 to 8 weeks. [9] Going the other direction, from Armour to Tirosint, the dose is typically increased by 10 to 15% to compensate for the loss of T3 contribution.

A practical conversion reference used by the HealthRX clinical team:

| Armour Thyroid | Approximate Tirosint Equivalent | |---|---| | 30 mg (1/2 grain) | 50 mcg | | 60 mg (1 grain) | 100 mcg | | 90 mg (1.5 grains) | 137 to 150 mcg | | 120 mg (2 grains) | 200 mcg | | 180 mg (3 grains) | 300 mcg |

These are approximate starting points. Recheck TSH, free T4, and free T3 at 6 to 8 weeks after conversion and adjust based on labs and symptoms.

Who Should Choose Armour Thyroid?

A patient is a reasonable candidate for Armour Thyroid when all of the following apply:

1. TSH has been within range on levothyroxine, yet fatigue, brain fog, or weight resistance persists after ruling out other causes.
2. Free T3 sits in the lower third of the reference range despite adequate free T4.
3. No personal history of atrial fibrillation, angina, or significant osteoporosis.
4. The prescriber can monitor free T3 in addition to TSH at each follow-up.
5. The patient understands the porcine origin and accepts it.

The Hoang 2013 data showed a meaningful preference signal in this profile, and the DIO2 genetic literature provides a plausible mechanistic rationale for the symptom gap. [6] [2]

Who Should Choose Tirosint?

Tirosint is the more logical choice when:

1. The patient has a documented absorptive disorder, including H. Pylori gastritis, celiac disease, short bowel syndrome, or post-bariatric anatomy.
2. TSH has been difficult to stabilize on tablet levothyroxine without an obvious dosing explanation.
3. Allergic or intolerance reactions to standard levothyroxine tablet excipients have occurred.
4. The patient cannot reliably separate their thyroid dose from food, coffee, or supplements.

Vita et al. 2014 provides the most direct support for this indication. [7] In patients whose TSH normalized on liquid L-T4 but not on tablets at the same dose, the benefit was biochemically confirmed and not attributable to placebo.

The Question of Patient Preference and Quality of Life

Patient-reported outcomes matter in thyroid care because TSH normalization does not always translate to subjective wellbeing. A 2020 survey-based study of 12,146 hypothyroid patients published in the European Journal of Endocrinology found that 46% of patients on levothyroxine monotherapy reported ongoing symptoms despite TSH within range, compared with 36% of those on combination T4/T3 therapy (P<0.001). [13]

Armour Thyroid delivers that combination in a single tablet. Tirosint can be paired with a separate liothyronine (T3) prescription for patients who need combination therapy but cannot tolerate DTE excipients, though this creates two prescriptions and a more complex dosing schedule.

Cost and Access

Tirosint is a branded product with no generic equivalent as of mid-2025. Cash-pay costs typically run $80, $180 per month depending on dose and pharmacy, though manufacturer coupons can reduce this substantially for insured patients. [1]

Armour Thyroid also remains branded (manufactured by AbbVie's Allergan unit), with periodic supply shortages affecting availability. Cash-pay prices are generally lower than Tirosint, averaging $40, $80 per month for typical doses.

Generic levothyroxine tablet costs $4, $12 per month at most retail pharmacies, which remains the cost benchmark against which both branded options are measured.

Monitoring and Follow-Up Protocols

Both agents require TSH rechecks 6 to 8 weeks after any dose change. For Armour Thyroid, free T3 should also be measured at steady state to confirm the T3 level is not running supraphysiologic. The American Thyroid Association recommends targeting free T3 within the reference range, not merely TSH normalization, when using combination therapy. [9]

For Tirosint patients with a history of absorption problems, a free T4 level at steady state confirms the dose is adequate. TSH alone may lag free T4 by weeks, particularly in patients with pituitary dysfunction. [9]

Annual bone density screening is appropriate for patients on Armour Thyroid who are postmenopausal, given the cumulative effect of even mild chronic T3 excess on trabecular bone. [14]